polyoma
bk
viru
bkv
nonenvelop
dna
viru
contain
circular
doublestrand
primari
infect
occur
childhood
larg
asymptomat
viru
subsequ
remain
latent
may
undergo
reactiv
immunosuppress
two
distinct
diseas
due
bkv
reactiv
recogn
polyomavirusassoci
nephropathi
renal
allograft
sever
postengraft
hemorrhag
cystiti
hc
hematopoiet
sct
hsct
diseas
involv
urinari
tract
uroepithelium
propos
main
site
bkv
latenc
recent
data
anoth
close
relat
polyoma
viru
jc
viru
show
gastrointestin
tract
may
latenc
interestingli
bkv
also
detect
pcr
stool
hospit
nonetheless
data
collect
singl
time
point
distinguish
primari
infect
reactiv
latent
infect
moreov
quantif
viral
load
lack
preclud
kinet
analysi
viral
reactiv
process
result
remain
unclear
whether
gastrointestin
tract
could
latenc
site
bkv
studi
hypothes
gastrointestin
tract
site
bkv
latenc
viral
reactiv
might
occur
immunosuppress
test
proposit
patient
popul
frequent
bkv
reactiv
would
need
studi
take
advantag
high
incid
bkv
reactiv
hsct
quantifi
prospect
fecal
bkv
load
consecut
hsct
patient
urin
bkv
load
quantifi
parallel
indic
possibl
concomit
uroepitheli
viral
reactiv
consecut
unselect
cohort
patient
undergo
hsct
queen
mari
hospit
hong
kong
studi
transplant
protocol
antimicrobi
prophylaxi
prevent
treatment
gvhd
also
inform
consent
obtain
patient
investig
approv
institut
review
board
accord
declar
helsinki
stool
sampl
collect
prospect
condit
day
hsc
infus
weekli
thereaft
day
discharg
method
stool
collect
viral
studi
briefli
stool
pass
bedpan
center
approxim
g
stool
collect
swirl
viral
transport
medium
dna
extract
aliquot
stool
suspens
qiaamp
blood
minikit
qiagen
basel
switzerland
elut
buffer
serial
spot
urin
sampl
ml
collect
weekli
interv
aforement
sampl
spun
g
min
dna
extract
free
urin
qiaamp
blood
minikit
elut
buffer
quantif
bkv
fecal
urinari
sampl
perform
qpcr
abi
prism
sequenc
detector
pe
biosystem
foster
citi
ca
usa
sequenc
qpcr
primer
taqman
probe
target
bkv
gene
amplif
protocol
pcr
precaut
qualiti
assur
sampl
test
triplic
viral
excret
express
bkv
genom
copi
per
fecal
sampl
g
stool
per
millilit
urin
stool
sampl
found
neg
bkv
qpcr
fresh
aliquot
obtain
origin
stock
stool
suspens
known
amount
bkv
plasmid
spike
dna
extract
sampl
qpcr
perform
experi
neg
stool
sampl
spike
control
bkv
plasmid
show
qpcr
result
correspond
amount
input
bkv
plasmid
therebi
exclud
fals
neg
due
pcr
failur
aris
possibl
nonspecif
interfer
stool
data
shown
studi
stringent
criteria
use
bkv
excret
fecal
urinari
defin
posit
two
sampl
posit
furthermor
surmis
three
consecut
posit
sampl
repres
continu
durat
week
might
biolog
relev
therefor
posit
sampl
defin
transient
posit
consecut
sampl
persist
posit
consecut
sampl
persist
posit
sampl
signific
peak
defin
peak
bkv
viral
load
increas
comparison
group
numer
data
evalu
categor
data
risk
factor
fecal
bkv
excret
evalu
binari
logist
regress
spss
chicago
il
usa
occurr
fecal
bkv
reactiv
depend
variabl
age
gender
type
hsct
autolog
vs
sibl
donor
vs
match
unrel
donor
sourc
hsc
bm
vs
peripher
blood
condit
regimen
occurr
acut
gvhd
hc
type
urinari
bkv
reactiv
covari
pvalu
consid
statist
signific
total
fecal
urinari
sampl
quantifi
bkv
dna
refer
herewith
bkv
short
median
number
sampl
evalu
per
patient
fecal
bkv
excret
detect
patient
transient
persist
persist
peak
figur
interestingli
eight
patient
fecal
bkv
alreadi
detect
marrow
condit
although
low
level
copiesstool
sampl
fecal
bkv
load
might
fluctuat
patient
persist
excret
three
patient
show
signific
peak
reach
copiessampl
day
posthsct
respect
declin
baselin
level
fecal
bkv
neg
patient
urinari
bkv
excret
detect
patient
transient
persist
persist
peak
three
differ
pattern
fecal
urinari
bkv
excret
could
distinguish
figur
pattern
patient
show
concomit
parallel
increas
declin
fecal
urinari
bkv
load
peak
fecal
urinari
bkv
excret
coincid
tempor
fecal
copiessampl
urinari
copiesml
day
fecal
copiessampl
urinari
copiesml
day
fecal
copiessampl
urinari
copiesml
day
three
patient
underw
allogen
hsct
signific
gvhd
first
patient
receiv
hsct
hlaident
sibl
develop
postengraft
hc
gross
hematuria
dysuria
day
subsequ
liver
skin
gvhd
month
second
patient
receiv
hsct
match
unrel
donor
develop
postengraft
hc
day
third
patient
receiv
hsct
hlaident
sibl
develop
acut
skin
gvhd
day
pattern
b
patient
show
signific
peak
urinari
bkv
excret
median
copiesml
occur
median
day
hsct
howev
none
patient
signific
peak
fecal
bkv
excret
eleven
patient
receiv
hsct
hlaident
sibl
two
match
unrel
donor
three
patient
receiv
autolog
hsct
patient
type
fecal
bkv
excret
persist
two
case
transient
eight
case
neg
six
case
pattern
c
patient
show
detect
peak
urinari
bkv
excret
eleven
patient
receiv
hsct
hlaident
sibl
three
match
unrel
donor
seven
patient
receiv
autolog
hsct
patient
fecal
bkv
excret
persist
one
transient
two
neg
patient
type
neg
transient
persist
persist
peak
urinari
fecal
bkv
excret
significantli
correl
kendal
taub
correl
coeffici
p
figur
noteworthi
one
patient
posit
fecal
bkv
excret
urinari
bkv
excret
hand
patient
posit
urinari
bkv
excret
includ
six
patient
viral
peak
show
fecal
bkv
encircl
point
figur
examin
risk
factor
clinic
correl
fecal
bkv
excret
clinicopatholog
paramet
patient
without
fecal
bkv
excret
compar
tabl
posit
stool
bkv
excret
significantli
associ
allogen
hsct
well
persist
peak
urinari
bkv
excret
p
binari
logist
regress
show
bkv
viruria
signific
risk
factor
fecal
bkv
excret
odd
ratio
confid
interv
although
bkv
reactiv
describ
solid
organ
allograft
mostli
renal
occasion
liver
heartlung
actual
frequenc
reactiv
lower
hsct
much
intens
immunosuppress
involv
therefor
hsct
repres
uniqu
opportun
address
issu
whether
bkv
might
latent
gastrointestin
tract
studi
fecal
bkv
load
first
prospect
quantit
analysi
fecal
bkv
load
hsct
show
posit
fecal
bkv
excret
hsct
patient
protocol
fecal
viral
quantif
valid
coronaviru
associ
sever
acut
respiratori
signific
peak
fecal
bkv
excret
detect
patient
pattern
case
show
consist
pattern
increas
peak
declin
parallel
concomit
urinari
bkv
reactiv
peak
coincid
day
fact
three
patient
undergon
allogen
hsct
develop
gvhd
typic
risk
factor
urinari
bkv
therefor
fecal
urinari
bkv
excret
probabl
reflect
viral
reactiv
consequ
sever
immunosuppress
definit
proof
bkv
reactiv
gastrointestin
tract
would
requir
detect
bkv
viral
antigen
colon
tissu
direct
demonstr
viral
particl
stool
electron
microscopi
detect
bkv
dna
gastrointestin
tract
situ
hybrid
absenc
late
gene
express
seroposit
patient
issu
warrant
investig
previou
studi
isol
colon
ad
hoc
stool
specimen
show
detect
bkv
gastrointestin
studi
examin
specimen
singl
time
point
actual
signific
presenc
bkv
remain
obscur
find
offer
much
rigor
result
provid
kinet
data
meaning
robust
isol
measur
inde
increas
declin
fecal
bkv
load
typic
might
expect
reactiv
latent
virus
organ
although
proposit
gastrointestin
tract
bkv
latenc
site
would
need
valid
patient
normal
peopl
may
provid
valuabl
insight
bkv
epidemiolog
seropreval
bkv
increas
children
high
bkv
seropreval
never
adequ
explain
assum
urin
mean
transmiss
fecalor
rout
howev
offer
addit
epidemiolog
explan
high
viral
preval
data
urinari
bkv
excret
studi
confirm
consist
link
allogen
hsct
gvhd
signific
bkv
viruria
sever
postengraft
previous
postul
immunosuppress
allow
uncheck
viral
replic
combin
subsequ
allogen
reactiv
viral
antigen
upon
hematopoiet
engraft
might
heighten
gvhd
lead
sever
hc
studi
howev
unabl
observ
appar
associ
fecal
bkv
excret
gut
gvhd
nevertheless
studi
contain
rel
small
number
patient
potenti
relationship
fecal
bkv
excret
gut
gvhd
would
need
examin
larger
number
hsct
recipi
observ
provid
two
posit
lead
futur
studi
firstli
factor
predispos
biolog
clinic
signific
bkv
latenc
gastrointestin
tract
evalu
particular
recent
studi
identifi
bkv
dna
sequenc
colorect
cancer
suggest
viru
may
function
pathogenesi
secondli
patient
demonstr
signific
fecal
bkv
excret
bm
condit
lower
report
stool
rectal
swab
sampl
hospit
children
base
detect
bkv
tantigen
whether
reflect
agerel
differ
bkv
fecal
excret
henc
differ
viral
epidemiolog
health
diseas
technic
differ
bkv
dna
detect
remain
determin
